Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Department of Health
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Department of Health
25 November 2011 (9.71 Kb 2 sec) |
This page was last updated: 24 November 2011